<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PHENYLEPHRINE HYDROCHLORIDE</span><br/>(fen-ill-ef'rin)<br/><span class="topboxtradename">AK-Dilate Ophthalmic, </span><span class="topboxtradename">Alconefrin, </span><span class="topboxtradename">Isopto Frin, </span><span class="topboxtradename">Mydfrin, </span><span class="topboxtradename">Neo-Synephrine, </span><span class="topboxtradename">Nostril, </span><span class="topboxtradename">Prefrin Liquifilm, </span><span class="topboxtradename">Rhinall, </span><span class="topboxtradename">Sinarest Nasal, </span><span class="topboxtradename">Sinex, </span><span class="topboxtradename">Vacon<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">alpha-adrenergic agonist</span>; <span class="classification">eye and nose preparation</span>; <span class="classification">mydriatic</span>; <span class="classification">decongestant</span><br/><b>Prototype: </b>Methoxamine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg chewable tablet; 0.125%, 0.16%, 0.5%, 1% nasal solution; 0.12%, 2.5%, 10% ophthalmic solution; 10 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Potent, synthetic, direct-acting sympathomimetic with strong alpha-adrenergic and weak beta-adrenergic cardiac stimulant actions.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Produces little or no CNS stimulation. Elevates systolic and diastolic pressures through arteriolar constriction; also constricts
         capacitance vessels and increases venous return to heart. Rise in BP causes reflex bradycardia. Topical applications to eye
         produce vasoconstriction and prompt mydriasis of short duration, usually without causing cycloplegia. Reduces intraocular
         pressure by increasing outflow and decreasing rate of aqueous humor secretion. Nasal decongestant action qualitatively similar
         to that of epinephrine but more potent and has longer duration of action.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Parenterally to maintain BP during anesthesia, to treat vascular failure in shock, and to overcome paroxysmal supraventricular
         tachycardia. Used topically for rhinitis of common cold, allergic rhinitis, and sinusitis; in selected patients with wide-angle
         glaucoma; as mydriatic for ophthalmoscopic examination or surgery, and for relief of uveitis.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Severe coronary disease, severe hypertension, ventricular tachycardia; narrow-angle glaucoma (ophthalmic preparations); pregnancy
         (category C), lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hyperthyroidism; diabetes mellitus; myocardial disease, cerebral arteriosclerosis, bradycardia; older adult patients; 21 d
         before or following termination of MAO inhibitor therapy. <b>Ophthalmic solution (10%):</b> Cardiovascular disease; diabetes mellitus; hypertension; aneurysms; infants.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypotension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM/SC</span> 110 mg (initial dose not to exceed 5 mg) q1015min as needed <span class="rdroute">IV</span> 0.10.18 mg/min until BP stabilizes; then 0.040.06 mg/min for maintenance<br/><br/><span class="indicationtitle">Ophthalmoscopy</span><br/><p>See Appendix A</p><br/><span class="indicationtitle">Vasoconstrictor</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Ophthalmic</span> See Appendix A1 <span class="rdroute">Intranasal</span> Small amount of nasal jelly placed into each nostril q34h as needed or 23 drops or sprays of 0.250.5%
               solution q34h as needed<br/><span class="rdage">Child:</span> <span class="rdroute">Intranasal</span>
<i> 23 drops or sprays of 0.125% solution q34h as needed; <i>612 y,</i> 23 drops or sprays of 0.25% solution q34h as needed<br/></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Instillation</span><br/><ul>
<li>Nasal preparations: Instruct patient to blow nose gently (with both nostrils open) to clear nasal passages before administration
            of medication.
         </li>
<li>Instillation (drops): Tilt head back while sitting or standing up, or lie on bed and hang head over side. Stay in position
            a few minutes to permit medication to spread through nose. (Spray): With head upright, squeeze bottle quickly and firmly to
            produce 1 or 2 sprays into each nostril; wait 35 min, blow nose, and repeat dose. (Jelly): Place in each nostril and
            sniff it well back into nose.
         </li>
<li>Clean tips and droppers of nasal solution dispensers with hot water after use to prevent contamination of solution. Droppers
            of ophthalmic solution bottles should not touch any surface including the eye.
         </li>
<li>Ophthalmic preparations: To avoid excessive systemic absorption, apply pressure to lacrimal sac during and for 12 min
            after instillation of drops.
         </li>
</ul><span class="adminroutetype">Subcutaneous/</span><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Give undiluted.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Dilute each 1 mg in 9 mL of sterile water.  <span class="methodtype">IV Infusion:</span> Further dilute each 10 mg in 500 mL D5W or NS (concentration: 0.2 mg/mL).  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give a single dose over 60 sec.  <span class="methodtype">IV Infusion:</span> Titrate to maintain BP.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Y-site:</span>
<b>Thiopental.</b>
</p>
<ul>
<li>Protect from exposure to air, strong light, or heat, any of which can cause solutions to change color to brown, form a precipitate,
                     and lose potency.
                  </li>
</ul>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Special Senses:</span>
<span class="speceff-common">Transient stinging,</span> lacrimation, brow ache, headache, blurred vision, allergy (pigmentary deposits on lids, conjunctiva, and cornea with prolonged
      use), increased sensitivity to light. <span class="speceff-common">Rebound nasal congestion</span> (hyperemia and edema of mucosa), <span class="speceff-common">nasal burning,</span> stinging, dryness, <span class="speceff-common">sneezing.</span>
<span class="typehead">CV:</span> Palpitation, tachycardia, bradycardia (overdosage), extrasystoles, hypertension. <span class="typehead">Body as a Whole:</span> Trembling, sweating, pallor, sense of fullness in head, tingling of extremities, sleeplessness, dizziness, light-headedness,
      weakness, restlessness, anxiety, precordial pain, <span class="speceff-common">tremor,</span>
<span class="speceff-life">severe visceral or peripheral vasoconstriction</span>, necrosis if IV infiltrates. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">ergot alkaloids</span>, <b>guanethidine,</b>
<b>reserpine,</b>
<span class="classification">tricyclic antidepressants</span> increase pressor effects of phenylephrine; <b>halothane,</b>
<b>digoxin</b> increase risk of arrhythmias; <span class="classification">mao inhibitors</span> cause hypertensive crisis; <b>oxytocin</b> causes persistent hypertension; <span class="classification">alpha blockers</span>, <span class="classification">beta blockers</span> antagonize effects of phenylephrine. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> Immediate IV; 1015 min IM/SC. <span class="typehead">Duration:</span> 1520 min IV; 30120 min IM/SC; 36 h topical. <span class="typehead">Metabolism:</span> Metabolized in liver and tissues by monoamine oxidase. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor pulse, BP, and central venous pressure (q25min) during IV administration.</li>
<li>Control flow rate and dosage to prevent excessive dosage. IV overdoses can induce ventricular dysrhythmias.</li>
<li>Observe for congestion or rebound miosis after topical administration to eye.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be aware that instillation of 2.510% strength ophthalmic solution can cause burning and stinging.</li>
<li>Do not exceed recommended dosage regardless of formulation.</li>
<li>Inform the physician if no relief is experienced from preparation in 5 d.</li>
<li>Be aware that systemic absorption from nasal and conjunctival membranes can occur, though infrequently (see <small>ADVERSE EFFECTS</small>). Discontinue drug and report to the physician if adverse effects occur.
         </li>
<li>Wear sunglasses in bright light because after instillation of ophthalmic drops, pupils will be large and eyes may be more
            sensitive to light than usual. Stop medication and notify physician if sensitivity persists beyond 12 h after drug has been
            discontinued.
         </li>
<li>Be aware that some ophthalmic solutions may stain contact lenses.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>